Eli Lilly and Co. and AstraZeneca have extended their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of solid tumors. The companies will now evaluate the safety and efficacy of a range of additional combinations across their portfolios. Lilly will lead the studies and both companies will contribute resources. Additional details and financial terms, were not disclosed. AZ’s anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), wil...